Cancer News, Research & Analysis
Time-sensitive and reliable coverage of pharmaceutical industry
developments, clinical trials, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €750/£675 a year per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna head office, Austria, European Union: +43 (0)1 71 71 8 900
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients
Patients can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. Adding CN to Immunotherapy for Metastatic Kidney Cancer Improves Survival
- 2. Curasight announces positive preclinical results with uTREAT in aggressive brain cancer
- 3. Ciltacabtagene Autoleucel Reduces Risk of Progression of Multiple Myeloma after Lenalidomide
- 4. 'Most horrible' brain tumor patients falling through healthcare cracks, study shows
- 5. New NCL Assessment of Sona's GNR Technology Highlights Process Improvement Success
- 6. Burning Rock Narrows Losses With Drug Research As New Driver
- 7. GEICAM Selects TransPerfect's Trial Interactive eTMF and TMF Management Solutions
- 8. PreCheck Health Services Inc. Announces the Launch of a Comprehensive Cancer Panel Using Next Generation Sequencing (NGS) Technology
- 9. Deerfield Management and the Deerfield Foundation Announce the Creation of the American Society of Hematology (ASH) Peter Steelman Scholar Award and the First Annual AML Summit to Advance Research for Acute Myeloid Leukemia
- 10. Insilico Medicine announces potential best-in-class pan-TEAD inhibitor candidate ISM6331 targeting advanced solid tumors
Last updated at 3:49 GMT
Hot News Makers
Health/Pharma Companies
-
67162.45
-
54353.08
-
21907.85
-
21239.72
-
9807.36
-
7159.34
-
6363.46
-
6275.43
-
6114.52
-
5842.93
Last updated at 3:10 GMT